KalVista Pharmaceuticals is presenting real-world and quality-of-life data on its oral, on-demand hereditary angioedema therapy at ACAAI26. Separate research co

KalVista Pharmaceuticals is presenting real-world and quality-of-life data on its oral, on-demand hereditary angioedema therapy at ACAAI26. Separate research covers adolescents, children and caregivers, widening the focus beyond adult patients.